idarubicin has been researched along with prednimustine in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Alberto, P | 1 |
| Barnadas, A; Casado, A; Clerigue, M; Cortés-Funes, H; Diaz-Rubio, E; García de Paredes, M; Jimeno, J; Mendiola, C; Rosell, R; Villar, A | 1 |
| Barbarano, L; Bernuzzi, P; Gargantini, L; Morra, E; Nosari, A; Pungolino, E; Santoleri, L | 1 |
2 trial(s) available for idarubicin and prednimustine
| Article | Year |
|---|---|
Phase II study of an oral combination of doxifluridine, prednimustine and idarubicin (FUPRIDA) for first line treatment of advanced breast cancer.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Floxuridine; Humans; Idarubicin; Middle Aged; Prednimustine | 1993 |
Combination of oral idarubicin and prednimustine in advanced breast cancer: a phase II study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Idarubicin; Middle Aged; Prednimustine; Treatment Outcome | 1997 |
2 other study(ies) available for idarubicin and prednimustine
| Article | Year |
|---|---|
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Treatment of patients with high-grade non-Hodgkin's lymphoma aged over 70 years with an all-oral regimen combining idarubicin, etoposide and alkylators.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Agranulocytosis; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Evaluation; Etoposide; Female; Follow-Up Studies; Humans; Idarubicin; Lymphoma, Non-Hodgkin; Male; Prednimustine; Thrombocytopenia; Treatment Outcome | 2000 |